Radiation Oncology

NCI-CCC Thoracic Tumor Board Question

Questions discussed in this category

In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?

If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this chan...

4 Answers available

Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?

If so, when and to what extent?

2 Answers available

How would you approach adjuvant therapy for a patient with pT2N2 lung adenocarcinoma who underwent an R1 resection and is not amenable to further surgical intervention?

NGS without any actionable mutations and PD-L1 TPS 15%. Would you offer chemotherapy, radiation, or immunotherapy and, if so, in what order?

1 Answer available

How do you approach adjuvant therapy for resected lung adenocarcinoma that was found unexpectedly postop to be N2?

Do you routinely offer post-operative adjuvant radiation in addition to chemotherapy? Are the results of the recently published negative phase II...

10 Answers available

How has COVID-19 altered your recommendations for invasive mediastinal staging for NSCLC?

Should staging and treatment decisions be made based on imaging alone?

2 Answers available

What is the best management for a local recurrence for a stage I NSCLC treated previously with SBRT?

Should fractionated EBRT be administered or can repeat SBRT be used?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.

Arch Surg,

Basic principles in surgical oncology.

Lancet, 1998 Jul 25

Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.

Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01

Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.

JAMA Oncol,

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.

Lancet Oncol, 2021 Dec 15

Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

BMC Cancer, 2019 Aug 19

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

J Thorac Oncol, 2023 Feb 23

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC.

J Clin Oncol, 2023 Jan 31

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

Cancer journal (Sudbury, Mass.), 2020 Nov/Dec

Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer: Implications for Oncogene-Driven Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021 Feb 12

Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.

Journal for immunotherapy of cancer, 2021 Aug

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.

International journal of cancer, 2019 Feb 19

EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.

The Lancet. Respiratory medicine, 2023 May 05

Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.

N Engl J Med, 2022 Apr 11

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.

Radiation Oncology

NCI-CCC Thoracic Tumor Board Question

Questions discussed in this category

Papers discussed in this category

Related Topics in Radiation Oncology